Show simple item record

dc.contributor.authorGalgiani, John N.
dc.contributor.authorAmpel, Neil M.
dc.contributor.authorBlair, Janis E.
dc.contributor.authorCatanzaro, Antonino
dc.contributor.authorGeertsma, Francesca
dc.contributor.authorHoover, Susan E.
dc.contributor.authorJohnson, Royce H.
dc.contributor.authorKusne, Shimon
dc.contributor.authorLisse, Jeffrey
dc.contributor.authorMacDonald, Joel D.
dc.contributor.authorMeyerson, Shari L.
dc.contributor.authorRaksin, Patricia B.
dc.contributor.authorSiever, John
dc.contributor.authorStevens, David A.
dc.contributor.authorSunenshine, Rebecca
dc.contributor.authorTheodore, Nicholas
dc.date.accessioned2016-12-14T21:02:32Z
dc.date.available2016-12-14T21:02:32Z
dc.date.issued2016-09-15
dc.identifier.citation2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis 2016, 63 (6):e112 Clinical Infectious Diseasesen
dc.identifier.issn1058-4838
dc.identifier.issn1537-6591
dc.identifier.doi10.1093/cid/ciw360
dc.identifier.urihttp://hdl.handle.net/10150/621661
dc.description.abstractIt is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.
dc.description.sponsorshipInfectious Diseases Society of America (IDSA)en
dc.language.isoenen
dc.publisherOXFORD UNIV PRESS INCen
dc.relation.urlhttp://cid.oxfordjournals.org/lookup/doi/10.1093/cid/ciw360en
dc.rights© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.en
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectcoccidioidomycosisen
dc.subjectantifungal treatmenten
dc.subjectcommunity acquired pneumoniaen
dc.subjecttravel historyen
dc.subjectimmunocompromised patientsen
dc.title2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosisen
dc.typeArticleen
dc.contributor.departmentUniv Arizona, Valley Fever Ctr Excellenceen
dc.contributor.departmentUniv Arizona, Div Infect Disen
dc.contributor.departmentUniv Arizona, Dept Rheumatolen
dc.identifier.journalClinical Infectious Diseasesen
dc.description.noteFirst published online: July 27, 2016en
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
dc.description.admin-noteDecision to use published version & no embargo since openly available on publisher site and nature of the work. Kimberly
refterms.dateFOA2018-06-26T05:32:38Z
html.description.abstractIt is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.


Files in this item

Thumbnail
Name:
IDSA 2016 Cocci GL.pdf
Size:
769.7Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record